Recently, Kintor Pharma scientists published results of a study titled " Inhibitory Effects of GT0918 on Acute Lung Injury and the Molecular Mechanisms of Anti-inflammatory Response " in the preprint journal bioRxiv. The study demonstrated that pruxelutamide (GT0918) is an effective therapeutic drug for severe COVID-19 patients, in addition to mild to moderate COVID-19 patients treatment. The Kintor team found that pruxelutamide could reduce cytokine release and suppress inflammatory responses through inhibiting NF-κB signaling and activating NRF2. Therefore, pruxelutamide exhibits potentials in regulating immune system function, maintaining immune homeostasis, and reducing the risk of cytokine release storm (CRS), acute respiratory distress syndrome (ARDS) and tissue damage . do